CD274 and glioblastoma: Similarly, the combination usage of axitinib (VEGFR1-3 inhibitor) and avelumab (anti-PD-L1) in unselected patients with recurrent GBM (NCT03291314) [162] failed to meet the expected outcome despite being approved as a first-line treatment strategy for advanced RCC [194].